– BELGIUM, Ghent – AgomAb Therapeutics NV announced the appointment of Colin Bond to its Board as an Independent Non-Executive Director.
“We welcome Colin to our Board of Directors,” said Board Chairman, David Epstein. “His extensive experience and expertise in the financial, pharmaceutical and public markets are of great value to Agomab as we progress towards the next growth stage for the company.”
Colin Bond will also join the Audit Committee as Chairman.
About Colin Bond
With an extensive career in finance that spans over three decades at leading international corporations, Colin Bond also brings fifteen years of experience as a CFO at listed biopharmaceutical companies in Switzerland, Germany, and the US.
“Agomab has continued to achieve its corporate objectives driven by its mission to improve the lives of patients living with fibrotic diseases. This is an exciting time to join the Board,” said Colin Bond. “I look forward to working with Tim Knotnerus and his highly focused team to support the company’s further trajectory.”
Most recently, Colin Bond served as CFO at Sandoz, where he successfully led the spin-out of the company from Novartis. Previously, he was CFO at Vifor Pharma where he was instrumental in the separation of Galenica from Vifor Pharma onto the Swiss Exchange in 2017. During his career, he also served as CFO of Evotec and worked as a pharmacist, auditor, and management consultant. Colin also has extensive Board experience and has served as Audit Committee Chair at Siegfried AG and BioPharma Credit PLC.
Colin Bond is a Fellow of the Institute of Chartered Accountants in England and Wales and a member of the Royal Pharmaceutical Society of Great Britain. Colin holds an MBA from London Business School.
About Agomab
Agomab is focused on achieving disease modification by modulating fibrosis and regeneration in chronic indications such as Fibrostenosing Crohn’s Disease and Idiopathic Pulmonary Fibrosis. We do this by targeting biologically validated pathways – including Transforming Growth Factor β and Hepatocyte Growth Factor – and by applying specialized capabilities in organ-restricted small molecules and high-affinity antibodies. With a differentiated clinical pipeline across several fibrotic disorders, end-to-end research and development capabilities, a proven BD track record, and a strong investor base, Agomab is building a leading biopharma company.
For more: https://agomab.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.